D
Dawn Ellis
Researcher at Wilmington University
Publications - 4
Citations - 1672
Dawn Ellis is an academic researcher from Wilmington University. The author has contributed to research in topics: Aggrecan & Aggrecanase. The author has an hindex of 4, co-authored 4 publications receiving 1625 citations.
Papers
More filters
Journal ArticleDOI
Purification and cloning of aggrecanase-1: a member of the ADAMTS family of proteins.
Micky D. Tortorella,Timothy Burn,Michael A. Pratta,Ilgar Abbaszade,Jeannine M. Hollis,Rui-Qin Liu,Stuart A. Rosenfeld,Robert A. Copeland,Carl P. Decicco,Richard Wynn,A. Rockwell,F. Yang,J. L. Duke,Kimberly A. Solomon,Henry J. George,Robert C. Bruckner,Hideaki Nagase,Yoshifumi Itoh,Dawn Ellis,Harold D. Ross,Barbara H. Wiswall,Kathleen Murphy,M.C. Hillman,Gregory Hollis,Robert C. Newton,Ronald L. Magolda,James M. Trzaskos,E. C. Arner +27 more
TL;DR: The identification of this protease provides a specific target for the development of therapeutics to prevent cartilage degradation in arthritis.
Journal ArticleDOI
Cloning and characterization of ADAMTS11, an aggrecanase from the ADAMTS family.
Ilgar Abbaszade,Rui-Qin Liu,Fude Yang,Stuart A. Rosenfeld,O. Harold Ross,John Link,Dawn Ellis,Micky D. Tortorella,Michael A. Pratta,Jeannine M. Hollis,Richard Wynn,J. L. Duke,Henry J. George,M.C. Hillman,Kathleen Murphy,Barbara H. Wiswall,Robert A. Copeland,Carl P. Decicco,Robert C. Bruckner,Hideaki Nagase,Yoshifumi Itoh,Robert C. Newton,Ronald L. Magolda,James M. Trzaskos,Gregory Hollis,Elizabeth C. Arner,Timothy Burn +26 more
TL;DR: A novel disintegrin metalloproteinase with thrombospondin motifs that possesses aggrecanase activity is identified and cloned, which has extensive homology to ADAMTS4 (aggrecanases-1) and the inflammation-associated gene ADAMts1, which is hypothesized to play a pivotal role in cartilage damage.
Journal ArticleDOI
Human Immunodeficiency Virus Type 1 Mutations Selected in Patients Failing Efavirenz Combination Therapy
Lee T. Bacheler,Elizabeth D. Anton,Phil Kudish,David Baker,Julie Bunville,Karen Krakowski,Laura Bolling,Monette Aujay,Xin Victoria Wang,Dawn Ellis,Mary F. Becker,Amy L. Lasut,Henry J. George,Daniel R. Spalding,Greg Hollis,Kenneth Abremski +15 more
TL;DR: The proportion of patients carrying NNRTI resistance mutations, usually K103N, increased dramatically at the time of initial viral load rebound in cases of treatment failure after exposure to efavirenz, and accumulated more slowly following the emergence of K103n mutant viruses.
Journal ArticleDOI
Identification of ADAM10 as a major source of HER2 ectodomain sheddase activity in HER2 overexpressing breast cancer cells.
Phillip Liu,Xiangdong Liu,Yanlong Li,Maryanne B. Covington,Richard Wynn,Reid Huber,M.C. Hillman,Gengjie Yang,Dawn Ellis,Cindy Marando,Kamna Katiyar,Jodi D. Bradley,Kenneth Abremski,Mark Stow,Mark Rupar,Jincong Zhuo,Yun-Long Li,Qiyan Lin,David M. Burns,Meizhong Xu,Colin Zhang,Ding-Quan Qian,Chunhong He,Vaqar Sharief,Lingkai Weng,Costas Agrios,Eric Shi,Brian Metcalf,Robert Newton,Steven M. Friedman,Wenqing Yao,Peggy A. Scherle,Gregory F. Hollis,Timothy Burn +33 more
TL;DR: In vitro studies demonstrate that in combination with low doses of Herceptin, selective ADAM 10 inhibitors decrease proliferation in HER2 overexpressing cell lines while inhibitors, that do not inhibit ADAM10, have no impact.